Windtree Therapeutics, Inc. (WINT)
| Market Cap | 2.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.29M |
| Shares Out | 510.18K |
| EPS (ttm) | -94.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,779 |
| Open | 4.310 |
| Previous Close | 4.340 |
| Day's Range | 4.010 - 4.410 |
| 52-Week Range | 4.010 - 35.100 |
| Beta | 0.61 |
| Analysts | Hold |
| Price Target | 18.00 (+339.02%) |
| Earnings Date | May 21, 2024 |
About WINT
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactan... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for WINT stock is "Hold" and the 12-month stock price forecast is $18.0.
News
Windtree Therapeutics Regains Compliance with Nasdaq
WARRINGTON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovati...
What made Windtree Therapeutics stock tank 20% on Monday?
Windtree Therapeutics Inc (NASDAQ: WINT) is down nearly 20% on Monday even though there hasn't been any specific news that may have caused that decline. Here's what may be weighing on Windtree Therap...
Windtree Therapeutics Announces Reverse Stock Split
WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovati...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innova...
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset ...
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
WARRINGTON, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
WARRINGTON, PA / ACCESSWIRE / January 26, 2024 / Windtree Therapeutics (NASDAQ:WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 mil...
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
WARRINGTON, PA / ACCESSWIRE / January 18, 2024 / Greater China holds a significant, if not the world's largest, acute heart failure patient population. It may be a market where drug treatment innovati...
Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for prod...
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute...
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
WARRINGTON, PA / ACCESSWIRE / December 19, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the...
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3
Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
This class of SERCA2a Activators selectively activates SERCA2a and may lead to novel therapies for heart failure beyond the Company's current lead program This class of SERCA2a Activators selectively ...
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
WARRINGTON, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
WARRINGTON, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
WARRINGTON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
WARRINGTON, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for...
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients Patent provides protection through late 2039 for drug candidates w...
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market
WARRINGTON, PA / ACCESSWIRE / August 16, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biotechnology company developing treatments for severe cardiovascular disorders. It is targeting patients...
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3; Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure
WARRINGTON, PA / ACCESSWIRE / July 25, 2023 / Windtree Therapeutics Inc. (NASDAQ:WINT) is looking to revolutionize acute care treatment for patients with serious conditions like acute heart failure (A...
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
WARRINGTON, PA / ACCESSWIRE / July 18, 2023 / The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 t...